Press Release
Dear Sir / Madam, We wish to inform that the USFDA inspected our formulations manufacturing facility at Baddi from 20th February 2017 to 1st March 2017. At the end of the inspection, there were 3 observations given under form 483. All these three observations are related to Pre-Approval Inspection (PAI) for a specific product filed. This product is yet to be manufactured or marketed in the US. The company is already in the process of responding... Credit Rating
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of CRISIL rating A1+ on the 250 crores Short Term Debt Programme (including Commercial Papers) of the Company. Newspaper Advertisements for Notice convening the meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors
Cadila Healthcare Ltd has submitted to BSE a copy of Newspaper Advertisements published in newspaper regarding notice convening the meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors of the Company scheduled on March 30, 2017. Zydus Cadila to launch tetravalent influenza vaccine in India
Vaccine offers protection from 4 influenza viruses - H1N1, H3N2, Type B (Brisbane) & Type B (Phuket) Zydus Pharma subsidiary gets approval for Oseltamivir capsules in USA
Zydus Pharma subsidiary Nesher Pharmaceuticals has received approval from the USFDA to sell Oseltamivir Phosphate capsules. The medication, an anti-viral used to treat influenza, has an estimated annual sales of $382 million in the US. Flu season in the US typically starts in October and goes on till March, which is the time sales of influenza medication is the highest. Zydus' Nesher Pharmaceuticals receives final approval from the USFDA for Oseltamivir Phosphate Capsules
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 27, 2017 titled "Zydus' Nesher Pharmaceuticals receives final approval from the USFDA for Oseltamivir Phosphate Capsules". Zydus Cadila to launch influenza fighting vaccine in India
The vaccine provides protection from four influenza viruses -- H1N1, H3N2, Type B (Brisbane) Zydus Cadila to launch Indias 1st Tetravalent Inactivated Influenza vaccine - VaxiFlu - 4
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 24, 2017, titled "Zydus Cadila to launch Indias 1st Tetravalent Inactivated Influenza vaccine - VaxiFlu - 4". Tribunal Convened Meeting on March 30, 2017
Cadila Healthcare Ltd has submitted to BSE a copy of notice of Tribunal Convened Meeting of the Equity Shareholders of the Company will be held on March 30, 2017. Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC)
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 23, 2017, titled "Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC)".